Współczesne zasady postępowania w zespole rozpadu guza nowotworowego
Contemporary approach in the management of tumor lysis syndrome. Tumor lysis syndrome (TLS) is defined as an oncology emergency, which occurs usually in patients with potentially curable neoplasms. TLS is characterized by a range of metabolic abnormalities due to release of intracellular products into the bloodstream, and may arise spontaneously or more often occurs within the first 24 to 72 h after the initiation of anticancer therapy. TLS results in hyperuricemia, hyperphosphatemia, hyperkalemia and hypocalcemia. These metabolic abnormalities may lead to life-threatening complications such as acute renal failure, heart arrhythmia, cardiac arrest, tetany, seizures, and sudden death. Classic prophylaxis and treatment of TLS consist of appropriate hydration and administration of allopurinol. Contemporary management of TLS includes injection of rasburicase, a recombinant form of urate oxidase.